Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.

Scientific reports - 16 Feb 2017

Huang Anfei, Peng Di, Guo Huanhuan, Ben Yinyin, Zuo Xiangyang, Wu Fei, Yang Xiaoli, Teng Fei, Li Zhen, Qian Xueming, Qin F Xiao-Feng

Abstract excerpt

Huge efforts have been devoted to develop therapeutic monoclonal antibodies targeting human Programmed death-ligand 1 (hPD-L1) for treating various types of human cancers. However, thus far there is no suitable animal model for evaluating the anti-tumor efficacy of such antibodies against hPD-L1. Here we report the generation of a robust and effective system utilizing hPD-L1-expressing mouse tumor cells to study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphocytes, Tumor-Infiltrating

Share to Myeloid Cells

Share to T-Lymphocyte Subsets

Share to Tumor Burden

Share to Tumor Microenvironment

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 28202921
DOI: 10.1038/srep42687
PMCID: PMC5311961

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.PMID 28202921Read ↗

Human and mouse PD-L1: similar molecular structure, but different druggability profilesSemantic proximity Read ↗

A novel humanized PD-1/PD-L1 mouse model permits direct comparison of anti-tumor immunity generated by FDA-approved PD-1 and PD-L1 inhibitorsSemantic proximity Read ↗

Research progress on the intrinsic non‑immune function of PD‑L1 in tumors (Review)Semantic proximity Read ↗

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in miceSemantic proximity Read ↗

An In Vivo Method for Diversifying the Functions of Therapeutic AntibodiesSemantic proximity Read ↗

Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use.Semantic proximity Read ↗

A comprehensive analysis of humanized mouse models for the study of cancer immunotherapiesSemantic proximity Read ↗

Recent Findings in the Regulation of Programmed Death Ligand 1 ExpressionSemantic proximity Read ↗

Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse ModelsSemantic proximity Read ↗

Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cellsSemantic proximity Read ↗

Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptorSemantic proximity Read ↗

Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.